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PERSPECTIVE
Galectin-3 prospects as a therapeutic 
agent for multiple sclerosis
Galectin-3 (Gal-3) in oligodendrocyte (OLG) differentiation: 
OLGs are the cells in charge of myelination in the central ner-
vous system (CNS), allowing rapid conduction of the neural 
action potential and giving trophic support to axons. OLGs un-
dergo a series of changes throughout their life cycle: first, upon 
neural stem cell commitment to the OLG lineage, cells referred 
to as OLG precursor cells (OPC) present a bipolar morphology, 
have proliferative and migratory capacity and express molecular 
markers like platelet-derived growth factor receptor alpha and 
neural/glial antigen 2; next, in an intermediate stage called pre-
OLG, OLGs are more ramified and express CNPase, Olig1 and 
O4, among others; finally, cells develop into myelin forming 
cells which express molecular markers like myelin basic pro-
tein (MBP), adenomatous polyposis polyposis and proteolipid 
protein (Franklin et al., 2017). Worth pointing out, the actin 
cytoskeleton plays an important role in OLG maturation, as it 
evolves from pro-polymerization to pro-depolymerization dy-
namics, which allows axon ensheathing. These mechanisms are 
controlled in part by the relationship between MBP and actin 
disassembly proteins such as cofilin-1 and gelsolin. The latter 
are normally sequestered and inactivated by phosphatidylinosi-
tol 4,5-bisphosphate present in the plasma membrane. When 
MBP is expressed in mature OLG, it competes with gelsolin and 
cofilin-1 for phosphatidylinositol 4,5-bisphosphate binding, 
displacing and hence activating them, to trigger the disassembly 
of actin filaments (Zuchero et al., 2018).
Gal-3, a β-galactoside binding lectin, has a myriad of func-
tions depending on cell type and context. It is widely described 
in immune responses presenting both pro- and anti-inflamma-
tory properties. Our group has thoroughly researched the role 
of this protein in OLG biology, first observing that LGALS3–/– 
mice had severe myelin defects, including fewer myelinated ax-
ons, decreased g-ratio and loosely wrapped myelin. Moreover, 
OLG treatment with media conditioned by microglia from wild 
type mice promoted OLG differentiation. However, this effect 
was impaired when OLG were cultured in media conditioned 
by LGALS3–/– microglia, suggesting that the expression of Gal-3 
by microglia is necessary for OLG maturation. In addition, us-
ing neurosphere cultures, our group has also shown that Gal-3 
promotes cellular commitment to the oligodendroglial lineage. 
Furthermore, these studies demonstrated that extracellular Gal-
3 derived from microglia exerted a dose-dependent pro-differ-
entiating effect in close relationship with the glycoconjugates 
present at the time of action, mainly in OPC (Figure 1) (Pas-
quini et al., 2011). Interestingly, extracellular Gal-3 accelerated 
OLG maturation in vitro by modulating Akt, Erk 1/2 and β-cat-
enin signaling pathways and cytoskeleton dynamics (Thomas 
and Pasquini, 2019). Briefly, extracellular Gal-3 activated Akt, 
possibly through the mTORC1 pathway, in tight relationship 
with Erk 1/2 inhibition, leading to increased MBP expression 
(Figure 1i). These pathways were also critical for the accelerat-
ed actin cytoskeleton dynamics observed with Gal-3 treatment 
(Figure 1ii). In summary, our results indicate that Gal-3 plays a 
key role in both OLG differentiation and myelination. 
Gal-3 in animal models of multiple sclerosis (MS): Autoim-
mune diseases or genetic defects, like MS or leukodystrophies, 
respectively, can cause dysfunction and consequent loss of 
OLG. In the course of MS, the inflammatory response gen-
erates OLG lesions which can in turn be followed by a repair 
response consisting in OPC activation, in which cells return to 
the cell cycle to proliferate and migrate, and recruitment to the 
damaged area. Once recruited, OPC may proliferate and dif-
ferentiate to form new myelin sheaths for axon remyelination 
and thereby restore saltatory conduction. However, this process 
often fails and thus leads to axonal damage and neuronal death, 
and eventual progressive disability (Franklin et al., 2017). The 
most frequent type of MS, called relapsing remitting MS, con-
sists in recurrent presentations of clinical signs followed by par-
tial or total recovery. After 10 or 15 years of illness, symptoms 
become progressive and lead to continuous clinical deteriora-
tion, a phase called secondary progressive MS (SPMS). Never-
theless, in some patients, MS is relentless from the beginning, 
which constitutes the primary progressive MS (PPMS) form. 
In this scenario, several efforts are being made all around the 
world to improve remyelination by approaching the migration, 
proliferation and differentiation of OLG in the site of injury. 
Research in this field relies on MS experimental demyelin-
ation models mediated by immunity, virus or toxins. Even if 
these models fail to replicate the full complexity and hetero-
geneity of MS features, they have allowed the development of 
various treatments. Experimental autoimmune encephalomy-
elitis is induced by immunization of mice with different myelin 
antigens such as myelin oligodendrocyte glycoprotein, MBP, 
proteolipid protein and myelin-associated glycoprotein. De-
spite experimental autoimmune encephalomyelitis widespread 
use, numerous beneficial effects obtained in this model have 
not been replicated in MS treatment. This model applied in 
LGALS3−/− mice displayed a decrease in CNS macrophage in-
filtration and in disease severity (Thomas and Pasquini, 2018), 
suggesting a key role for Gal-3 in promoting inflammation by 
leukocyte recruitment (Figure 1). In contrast, further studies 
in this model showed a Gal-3-induced neuroprotective role 
through cell debris removal, axon regeneration and remyelin-
ation (Itabashi et al., 2018).
Several authors hypothesize that environmental factors such 
as viral infections are involved in MS and may actually trigger 
the disease, which led to the development of virus-induced MS 
models like Theiler’s Murine Encephalomyelitis Virus (TMEV) 
infection. Subventricular zone (SVZ) cell proliferation may 
decrease as a consequence of MS-induced inflammation and 
thus hinder recovery. Gal-3 expression increases in active hu-
man MS lesions (Stancic et al., 2011), periventricular regions 
in human MS and after murine TMEV infection, whereas Gal-
3 loss restores SVZ proliferation in the TMEV model through a 
reduction in the number of immune cells (James et al., 2016).
Our group has studied Gal-3 involvement in the demyelin-
ation/remyelination process using the cuprizone (CPZ) model 
(Figure 1), in which 8-week-old LGAL3−/− and wild type mice 
were fed a diet containing 0.2% CPZ w/w for 6 weeks to eval-
uate demyelination, followed by two more weeks on a CPZ-
free diet to assess remyelination. CPZ administration produces 
massive demyelination in the CNS through pathogenic T 
cell-independent mechanisms, the corpus callosum being par-
ticularly affected. CPZ administration allows the investigation 
of the remyelination process independently of peripheral im-
mune system contribution, as the model keeps the blood-brain 
barrier (BBB) intact. Both in 8-week-old LGALS3−/− and wild 
type mice, CPZ administration induces demyelination up to the 
fifth week of treatment. However, OPC response to demyelin-
ation in LGALS3−/− exhibits reduced branching, which indicates 
reduced OPC differentiation and is in line with our previous 
results showing Gal-3 participation in OLG differentiation. 
Most interestingly, wild type mice show spontaneous remyelin-
ation during the fifth week of CPZ treatment even if the toxic 
diet is kept during six weeks. In contrast, LGALS3−/− mice suffer 
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continuous demyelination up to the sixth week with a sharp as-
troglial response. Gal-3 is upregulated in microglia in CPZ-in-
duced demyelination and kept absent in astroglial cells. In 
addition, only wild type mice show ED1 (CD68) expression and 
TREM-2b upregulation during CPZ-induced demyelination, 
whereas LGALS3−/− mice display a large number of microglial 
cells which express activated caspase-3. Phagocytosis of myelin 
debris by microglia in CPZ demyelination requires phagocytic 
receptor TREM-2b expression and is essential to the onset of 
remyelination through oligodendroglial differentiation (Thom-
as and Pasquini, 2018). Strikingly, myelin phagocytosis relies 
on CR3/MAC-1 and SRAI/II, in turn regulated by Gal-3-de-
pendent activation of PI3K; therefore, myelin phagocytosis by 
LGALS3−/− microglia is usually deficient (Thomas and Pasquini, 
2018). In agreement with the TMEV model described above 
(James et al., 2016), Gal-3 regulates SVZ progenitor response 
to CPZ-induced demyelination, asits loss is associated with 
increased SVZ progenitor migration to demyelinated regions 
(Hillis et al., 2016).
Taken together, the results described so far demonstrate that 
Gal-3 acts as a regulator of the microglial response to promote 
remyelination (Thomas and Pasquini, 2018). 
Subsequent studies by our group further showed an in-
crease in metalloproteinase-3 expression and a decrease in 
CD45+, TNFα+ and TREM-2b+ cells during remyelination only 
in wild type mice, parameters which remained unaltered in 
LGALS3−/− mice during demyelination and remyelination. Ul-
trastructural studies following remyelination revealed defective 
myelin sheaths and collapsed axons in the corpus callosum of 
LGALS3−/− mice but no relevant myelin disruption in wild type 
mice. These results add up to the knowledge of the mechanisms 
underlying Gal-3 impact on remyelination, as they show that 
the tuning of microglial cells involves the modulation of metal-
loproteinase activity (Thomas and Pasquini, 2018). 
Gal-3 in MS: The role of Gal-3 in patients diagnosed with MS 
has been scarcely documented so far. It was recently shown that 
OPC treated with cerebrospinal fluid (CSF) obtained from pa-
tients with PPMS presented a significantly more ramified mor-
phology than control CSF accompanied by a pro-differentiating 
transcriptome, as evidenced by lower platelet-derived growth 
factor receptor α and LINGO1 mRNA levels and higher MAG 
mRNA. However, this transcriptome was different than that of 
normal OPC. Of note, this report showed the upregulation of 
the LGALS3 gene only in OPC treated with CSF from PPMS 
patients (Figure 1), establishing a link between the upregula-
tion of LGALS3 and the increase in OPC ramification. These 
findings received support from similar studies in post mortem 
human brain tissue from patients with PPMS (Haines et al., 
2015). 
It should be pointed out that autoimmune diseases such as MS 
present an aberrant glycosylation pattern. For instance, IgG from 
MS patients CSF exhibits a greater component of N-acetylglucos-
amine but lesser residues of sialic acid and galactose, the natural 
ligand of Gal-3 (Wuhrer et al., 2015). Given that proteins in gen-
eral have a smaller amount of galactose residues in the course of 
MS, Gal-3 may not be able to exert its pro-differentiating action 
on OLG, either through higher secretion rates by microglia or 
OLG themselves.
Furthermore, sera from patients with SPMS present auto-an-
tibodies against Gal-3, which could be in part responsible for 
the progressive damage to the BBB perceived in patients with 
MS (Nishihara et al., 2017). As part of the same study, the 
authors also determined that Gal-3 bound to the membrane 
of brain microvascular endothelial human cells (BMEC) was 
a target for the auto-antibodies present in sera from patients 
with SPMS but not in sera from healthy or other CNS illnesses 
patients. These authors also inhibited the expression of Gal-3 
in these cells, which triggered an increase in the expression of 
intracellular adhesion molecule 1 (ICAM-1) and p-NFκB p65, 
both of them described as responsible for the leak of leukocytes 
to the CNS. Taken together, these results suggest that Gal-3 
positively influences OLG differentiation in human brain tissue 
with MS and drives a downregulation of ICAM-1 in BMEC, 
thereby mediating a protective effect and highlighting its poten-
tial therapeutic in MS (Figure 1iii).
In summary, the findings obtained in different MS animal 
models such as experimental autoimmune encephalomyeli-
tis, CPZ and TMEV support the notion that Gal-3 is secreted 
by microglia, although the exact role of this secretion has not 
been fully elucidated yet and seems controversial (Hillis et al., 
2016; Thomas and Pasquini, 2019). For instance, it is known 
that Gal-3 may be secreted through a non-classical pathway 
and/or by exosomes. Our studies have demonstrated that Gal-
3 derived from microglia exerts a pro-differentiating effect on 
OLG during CPZ-induced demyelination, favoring the onset 
of remyelination (Pasquini et al., 2011; Thomas and Pasquini, 
2018). Gal-3 modulates microglia toward a phagocytic and an-
ti-inflammatory M2 phenotype, which increases the removal 
of myelin debris interfering with oligodendroglial differentia-
tion (Thomas and Pasquini, 2018; Itabashi et al., 2018). Some 
studies, however, indicate that Gal-3 exacerbates the disease, a 
discrepancy probably explained by the use of different demye-
linating models which simulate distinct MS features (James et 
al., 2016; Thomas and Pasquini, 2018). Our in vitro studies have 
elucidated that Gal-3 pro-differentiating effect from a mecha-
nistic point of view, demonstrating that Gal-3 drives early OLG 
process outgrowth and branching through enhanced actin as-
sembly and a decrease in Erk 1/2 activation, and also regulates 
OLG maturation by inducing Akt activation and an increase in 
MBP expression, promoting gelsolin release and actin cytoskel-
eton disassembly. Therefore, Gal-3 expressed by microglial cells 
could favor the onset of remyelination through the induction 
of M2 cell polarization and/or by a direct effect on OLG differ-
entiation. Furthermore, recent evidence has strongly supported 
Gal-3 involvement in MS disease. Diminished expression of 
Gal-3 in BMEC increases ICAM-1 and leukocyte infiltration to 
the CNS (Nishihara et al., 2017), although Gal-3 expressed by 
these cells binds to autoantibodies from SPMS patients, which 
leads to BBB damage. In addition, Gal-3 upregulation in OPC 
treated with PPMS CSF culture promotes OPC ramification 
(Haines et al., 2015). However, and possibly due to an aberrant 
glycosylation pattern in MS (Wuhrer et al., 2015), Gal-3 cannot 
bind properly to glycoconjugates to exert its pro-differentiation 
activity and lead to fully mature OLG. Taken together, these 
results support Gal-3 as a novel extracellular mediator of glial 
crosstalk to promote accelerated OLG maturation and to favor 
remyelination. Future studies will be necessary to evaluate pos-
sible pathways for non-invasive delivery of Gal-3 to the CNS 
and strategies to specifically target oligodendroglial precursors. 
These studies may have major significance in the development 
of future therapies for a variety of demyelinating diseases and 
especially for MS.
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Figure 1 Gal-3 influencing OLG differentiation and (re)myelination. 
Spectrum analysis adopted ICBM 152 and imagetwork in depression patients, and blue represents brain regions with decreasing node degree of Gal-3 
expressed by microglial cells during remyelination, favors an M2 microglial phenotype and, therefore, enhances myelin phagocytosis through phagocytic 
receptors and consequently, OLG differentiation. In OLG precursor cells (OPC), (i) extracellular Gal-3 activates Akt, possibly through the mTORC1 path-
way, in tight relationship with Erk 1/2 inhibition, leading to increased MBP expression. (ii) These pathways are also critical for the accelerated actin cyto-
skeleton dynamics observed with Gal-3 treatment. Also, microglia-released Gal-3 induces OLG fate in neural stem cells. (iii) Gal-3 downregulation in brain 
microvascular endothelial human cells, decreases intracellular adhesion molecule 1 to impede leukocyte infiltration. Furthermore, Gal-3 has proven to be 
a target for antibodies in primary progressive multiple sclerosis (PPMS) cerebrospinal fluid (CSF) and in OPC, treatment with PPMS CSF, increases Gal-3 
expression and branching (Thomas and Pasquini, 2018). OLG: Oligodendrocyte; Gal-3: galectin-3; BBB: blood-brain barrier; MS: multiple sclerosis; IGFR-
1: insulin-like growth 1-receptor; ICAM-1: intercellular adhesion molecule 1. 
